President Trump and FDA commissioner Stephen Hahn at the White House in Washington on March 19, 2020 (Yuri Gripas, Sipa via AP Images)
April 21, 2020 02:03 PM EDTUpdated April 22, 10:33 AM
R&D
Coronavirus

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

John Carroll

Editor & Founder

Just weeks fol­low­ing the FDA’s emer­gency ap­proval of hy­drox­y­chloro­quine af­ter Pres­i­dent Trump re­peat­ed­ly ad­vo­cat­ed its use for Covid-19, new da­ta from a quick VA study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times